Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation

Completed · Not applicable

Conditions studied: Liver Neoplasms

In brief

The purpose of this study is to determine the efficacy of the Definity (perflutren lipid microsphere Injectable Suspension) ultrasound contrast agent in identifying small tumors (hepatomas \& metastases) within the liver. Primary objective: To estimate the increase in conspicuity of small intrahepatic tumors with contrast-enhanced sonography Secondary Objectives: To estimate the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography

Key facts

Study ID

NCT00584402

Run by

University of California, Davis

People needed

8

Starts

2007-04-01

Expected to finish

2009-03-01

Last updated by the study team

2017-07-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with primary hepatocellular carcinoma (HCC) or secondary (metastatic) carcinoma of the liver who have been referred for ultrasound-guided radiofrequency ablation (RFA) treatment
• Recent (within 90 days) CT or MRI scan with report of one or more tumors ≤ 1.5 cm in diameter
• Patient is stable and is to be managed conservatively (i.e. non-surgically)
• 18 years of age or older
• Ability and willingness to provide written informed consent

You may not qualify if…

• Known or suspected cardiac shunt(s)
• Known sensitivity to octafluoropropane
• Pregnant or breastfeeding

Where it is running

• UC Davis Medical Center — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.